D-Sight secures €2 million to advance clinical validation of its neuroprotective therapies in a round led by Clave Capital

by CLAVE

Founded to translate cutting-edge neuroscience research into novel ophthalmic solutions, D-Sight is developing first-in-class neuroprotective drugs aimed at preserving retinal neurons and preventing i...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Xcalibur Smart Mapping strengthens its g...

by MCH Private Equity

​Xcalibur Smart Mapping, recognised as the global leader in airborne...

Photos Stream